Phase II study of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer

Phase II study of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer - Phase II study of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006332

Enrollment

Registered

2011-09-12

Start date

2011-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced pancreatic cancer

Interventions

Induction GS: S-1 60/80/100 mg/day based on BSA, from the evening of day 1 to the morning of day 15, q3w, GEM 1000 mg/m2, day8 and 15 S-1+RT: S-1 80/100/120 mg/day based on BSA, day1-14 and 22-3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Histologically or cytologically proven adenocarcinoma (2)unresectable locally advanced pancreatic cancer without distant metastases (3)no evidence of gastroduodenal invasion or obstruction (4)ECOG PS 0 or 1 (5)No prior chemotherapy or radiotherapy (6)Written informed consent (7)Adequate organ function

Exclusion criteria

Exclusion criteria: (1)severe concurrent disease (2)interstitial pneumonia, severe pulmonary emphysema or active pnemonia (3)mental disorder (4)active concomitant malignancy (5)moderate or severe diarrhea, hemorrhagic colitis or peptic ulcer (6)severe drug hypersensitibity (7)pregnant or lactating females (8)regular use of phenytoin, warfarin or frucitocin (9)Under treatment with systemic steroid (10)fever of 38 degrees centigrade or higher, or infection requiring systemic treatment (11)inappropriate for entry onto the study, as diagnosed by primary physician

Design outcomes

Primary

Measure	Time frame
1-year survival rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026